MARKET

EPRX

EPRX

Eupraxia Pharmac
NASDAQ
6.28
+0.41
+6.98%
After Hours: 6.16 -0.12 -1.91% 17:01 12/05 EST
OPEN
5.94
PREV CLOSE
5.87
HIGH
6.35
LOW
5.87
VOLUME
179.11K
TURNOVER
--
52 WEEK HIGH
7.19
52 WEEK LOW
2.680
MARKET CAP
318.07M
P/E (TTM)
-7.6970
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at EPRX last week (1124-1128)?
Weekly Report · 4d ago
Weekly Report: what happened at EPRX last week (1117-1121)?
Weekly Report · 11/24 09:44
Weekly Report: what happened at EPRX last week (1110-1114)?
Weekly Report · 11/17 09:44
Wall Street Analysts Think Eupraxia Pharmaceuticals Inc. (EPRX) Could Surge 75.08%: Read This Before Placing a Bet
NASDAQ · 11/14 14:55
Eupraxia Pharmaceuticals Reports Promising 52-Week Data for EoE Treatment
TipRanks · 11/13 22:44
Eupraxia Pharmaceuticals’ EP-104GI shows efficacy in follow-up esophagitis data
TipRanks · 11/13 22:15
Eupraxia Pharma Announces Second Set Of 52-Week Follow Up Data From Ongoing Phase 1b/2a RESOLVE Trial Evaluating Single Administration EP-104GI For EoE Treatment
Benzinga · 11/13 22:04
Eupraxia Reports Durable 52-Week Symptom Relief With EP-104GI in Eosinophilic Esophagitis Trial
Reuters · 11/13 22:00
More
About EPRX
Eupraxia Pharmaceuticals Inc. is a clinical-stage biotechnology company. The Company is focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. DiffuSphere, a proprietary, polymer-based micro-sphere technology, is designed to facilitate targeted drug delivery of both existing and novel drugs. The Company’s EP-104GI is in a Phase Ib/IIa trial, the RESOLVE trial, for the treatment of eosinophilic esophagitis (EoE). EP-104GI is administered as an injection into the esophageal wall, providing local delivery of drug. The Company also completed a Phase IIb clinical trial (SPRINGBOARD) of EP-104IAR for the treatment of pain due to knee osteoarthritis. In addition, the Company is developing a pipeline of later and earlier-stage long-acting formulations. Its potential pipeline indications include candidates for other inflammatory joint indications and oncology.

Webull offers Eupraxia Pharmaceuticals Inc stock information, including NASDAQ: EPRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, EPRX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading EPRX stock methods without spending real money on the virtual paper trading platform.